Effect of nebicapone (BIA 3-202) on the the pharmacokinetics of levodopa and catechol O-methyltransferase (COMT) activity in patients with Parkinson's disease

被引：0
|
作者：
Almeida, Luis
Ferreira, Joaquim
Nunes, Teresa
Machado, Rita
Torrao, Leonel
Costa, Joana
Soares, Eva
Rocha, Jose
Falcao, Amilcar
Wright, Lyndon
Soares-da-Silva, Patricio
机构：
[1] Hosp Santa Maria, Dept Neurol, Lisbon, Portugal
[2] Hlth, Catanhede, Portugal
来源：
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 2007年 / 63卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：784 / 785
页数：2
相关论文
共 50 条
  • [21] The effect of monoamine oxidase B (MAOB) and catechol-O-methyltransferase (COMT) polymorphisms on levodopa therapy in patients with sporadic Parkinson's disease
    Bialecka, M
    Drozdzik, M
    Klodowska-Duda, G
    Honczarenko, K
    Gawronska-Szklarz, B
    Opala, G
    Stankiewicz, J
    ACTA NEUROLOGICA SCANDINAVICA, 2004, 110 (04): : 260 - 266
  • [22] Association Between Catechol-O-Methyltransferase (COMT) Gene Polymorphisms, Parkinson's Disease, and Levodopa Efficacy
    Yin, Bowen
    Chen, Yongqian
    Zhang, Limei
    MOLECULAR DIAGNOSIS & THERAPY, 2014, 18 (02) : 253 - 260
  • [23] Effect of 3 Single-Dose Regimens of Opicapone on Levodopa Pharmacokinetics, Catechol-O-Methyltransferase Activity and Motor Response in Patients With Parkinson Disease
    Rocha, Jose-Francisco
    Ferreira, Joaquim J.
    Falcao, Amilcar
    Santos, Ana
    Pinto, Roberto
    Nunes, Teresa
    Almeida, Luis
    Soares-da-Silva, Patricio
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2016, 5 (03): : 232 - 240
  • [24] Effects of tolcapone, a catechol-O-methyltransferase inhibitor, on motor symptoms and pharmacokinetics of levodopa in patients with Parkinson's disease
    M. Yamamoto
    M. Yokochi
    S. Kuno
    Y. Hattori
    Y. Tsukamoto
    H. Narabayashi
    H. Tohgi
    Y. Mizuno
    H. Kowa
    N. Yanagisawa
    I. Kanazawa
    Journal of Neural Transmission, 1997, 104 : 229 - 236
  • [25] Effects of tolcapone, a catechol-O-methyltransferase inhibitor, on motor symptoms and pharmacokinetics of levodopa in patients with Parkinson's disease
    Yamamoto, M
    Yokochi, M
    Kuno, S
    Hattori, Y
    Tsukamoto, Y
    Narabayashi, H
    Tohgi, H
    Mizuno, Y
    Kowa, H
    Yanagisawa, N
    Kanazawa, I
    JOURNAL OF NEURAL TRANSMISSION, 1997, 104 (2-3) : 229 - 236
  • [26] No association between Parkinson's disease and low-activity alleles of catechol O-methyltransferase
    Hoda, F
    Nicholl, D
    Bennett, P
    Arranz, M
    Aitchison, KJ
    AlChalabi, A
    Kunugi, H
    Vallada, H
    Leigh, PN
    Chaudhuri, KR
    Collier, DA
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1996, 228 (03) : 780 - 784
  • [27] Genotypes of catechol-O-methyltransferase and response to levodopa treatment in patients with Parkinson's disease
    Lee, MS
    Lyoo, CH
    Ulmanen, I
    Syvänen, AC
    Rinne, JO
    NEUROSCIENCE LETTERS, 2001, 298 (02) : 131 - 134
  • [28] What is the impact of catechol-O-methyltransferase (COMT) on Parkinson's disease treatment?
    Salamon, Andras
    Zadori, Denes
    Szpisjak, Laszlo
    Klivenyi, Peter
    Vecsei, Laszlo
    EXPERT OPINION ON PHARMACOTHERAPY, 2022, 23 (10) : 1123 - 1128
  • [29] Kinetic inhibitory profile of BIA 3-202, a novel fast tight-binding, reversible and competitive catechol-O-methyltransferase inhibitor
    Bonifácio, MJ
    Vieira-Coelho, MA
    Soares-da-Silva, P
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2003, 460 (2-3) : 163 - 170
  • [30] The influence of catechol-O-methyltransferase (COMT) polymorphism on excessive daytime sleepiness in patients with Parkinson's disease
    Opala, G.
    Boczarsko-Jedynak, M.
    Lasinska-Myga, B.
    Smilowski, M.
    Klodowska-Duda, G.
    Bialecka, M.
    MOVEMENT DISORDERS, 2008, 23 (01) : S288 - S289
12345